<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174849</url>
  </required_header>
  <id_info>
    <org_study_id>605810</org_study_id>
    <secondary_id>ACTRN12610000544077</secondary_id>
    <nct_id>NCT01174849</nct_id>
  </id_info>
  <brief_title>Pneumococcal Vaccines Early and in Combination</brief_title>
  <acronym>PREVIX_COMBO</acronym>
  <official_title>A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies School of Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menzies School of Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an early schedule of a combination of three
      doses of PHiD-CV and one dose of PCV13, is superior to three doses of either PCV13 or
      PHiD-CV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aboriginal children in the Northern Territory (NT) have high rates of otitis media caused by
      non-capsular H. influenzae (NCHi) and pneumococci. Pneumococcal conjugate vaccine has
      effectively reduced disease caused by the 7 serotypes. Rates of non-vaccine serotype otitis
      media (OM), particularly 19A is increasing, and NCHi continues to be a major pathogen in
      perforations. Parallels with pneumonia are highly probable in this population. Vaccines with
      expanded and early age protection are needed.

      In early 2009 GSK's pneumococcal H. influenzae protein D conjugate vaccine (PHiD-CV) was
      licensed in Australia. Compared to the current vaccine, 7PCV, this vaccine offers protection
      from pneumococcal serotypes 1, 5, 7F as well as NCHi (which is a primary pathogen of OM, and
      possibly pneumonia). However by 2010, a new generation of Wyeth's 7PCV, PCV13 will also be
      licensed in Australia. Compared to PHiD-CV this vaccine offers protection from additional
      serotypes 3, 6A and 19A, however it does not offer protection from NCHi infection. There is
      no empirical evidence to suggest that either vaccine will have superior clinical efficacy for
      otitis media or pneumonia in high-risk children. The novel combination strategy proposed for
      this trial has the potential to provide the best of both vaccines.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>7 months of age</time_frame>
    <description>At 7 months of age, the overall and serotype specific (particularly serotype 19A and HiD) a IgG Geometric Mean Concentration (GMC) b proportion of children with IgG GMC above threshold (0.35 microg/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>nasopharyngeal carriage</measure>
    <time_frame>7 months of age</time_frame>
    <description>At 7 months of age, the proportion of children with any carriage of serotype 19A pneumococci</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nasopharyngeal carriage</measure>
    <time_frame>7 months of age</time_frame>
    <description>At 7 months of age, the proportion of children with any carriage of non-capsular H. influenzae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>otitis media</measure>
    <time_frame>7 months of age</time_frame>
    <description>At 7 months of age, the proportion of children with any otitis media.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">425</enrollment>
  <condition>Otitis Media</condition>
  <arm_group>
    <arm_group_label>Synflorix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COMBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COMBINATION SCHEDULE of comparator vaccine 1 and comparator vaccine 2 Synflorix at 1,2,4 months then Prevenar13 at 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synflorix</intervention_name>
    <description>The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.</description>
    <arm_group_label>Synflorix</arm_group_label>
    <other_name>PHiD-CV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevenar13</intervention_name>
    <description>The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.
Active ingredients
Each 0.5 mL dose contains:
2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium.</description>
    <arm_group_label>Prevenar13</arm_group_label>
    <other_name>PCV13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COMBO</intervention_name>
    <description>COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.</description>
    <arm_group_label>COMBO</arm_group_label>
    <other_name>Combination schedule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Indigenous infants

          -  4 to 6 weeks of age

          -  Living in remote communities that have provided signed Expressions of Interest in
             participating in PREV-IX_COMBO trial

          -  Intend to remain in their community until their baby is 7 months of age

          -  Eligible for routine vaccinations.

        Exclusion Criteria:

          -  Prior adverse reaction to pneumococcal conjugate vaccines according to Australian
             Immunization Handbook.

          -  Gestational age &lt; 32 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>38 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda J Leach, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menzies School of Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Menzies School of Health Research</name>
      <address>
        <city>Darwin</city>
        <state>Northern Territory</state>
        <zip>0811</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Morris PS, Leach AJ, Silberberg P, Mellon G, Wilson C, Hamilton E, Beissbarth J. Otitis media in young Aboriginal children from remote communities in Northern and Central Australia: a cross-sectional survey. BMC Pediatr. 2005 Jul 20;5:27.</citation>
    <PMID>16033643</PMID>
  </reference>
  <reference>
    <citation>Leach AJ, Morris PS. The burden and outcome of respiratory tract infection in Australian and aboriginal children. Pediatr Infect Dis J. 2007 Oct;26(10 Suppl):S4-7.</citation>
    <PMID>18049380</PMID>
  </reference>
  <reference>
    <citation>Leach AJ, Morris PS, Mathews JD; Chronic Otitis Media Intervention Trial - One (COMIT1) group. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatr. 2008 Jun 2;8:23. doi: 10.1186/1471-2431-8-23.</citation>
    <PMID>18513453</PMID>
  </reference>
  <reference>
    <citation>Leach AJ, Morris PS, Mackenzie G, McDonnell J, Balloch A, Carapetis J, Tang M. Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population. Vaccine. 2008 Jul 23;26(31):3885-91. doi: 10.1016/j.vaccine.2008.05.012. Epub 2008 May 27.</citation>
    <PMID>18562052</PMID>
  </reference>
  <reference>
    <citation>Leach AJ, Morris PS, McCallum GB, Wilson CA, Stubbs L, Beissbarth J, Jacups S, Hare K, Smith-Vaughan HC. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis. 2009 Aug 4;9:121. doi: 10.1186/1471-2334-9-121.</citation>
    <PMID>19650933</PMID>
  </reference>
  <reference>
    <citation>Mackenzie GA, Carapetis JR, Leach AJ, Morris PS. Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination. BMC Pediatr. 2009 Feb 19;9:14. doi: 10.1186/1471-2431-9-14.</citation>
    <PMID>19228431</PMID>
  </reference>
  <reference>
    <citation>Leach AJ, Boswell JB, Asche V, Nienhuys TG, Mathews JD. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatr Infect Dis J. 1994 Nov;13(11):983-9.</citation>
    <PMID>7845752</PMID>
  </reference>
  <reference>
    <citation>Smith-Vaughan H, Byun R, Nadkarni M, Jacques NA, Hunter N, Halpin S, Morris PS, Leach AJ. Measuring nasal bacterial load and its association with otitis media. BMC Ear Nose Throat Disord. 2006 May 10;6:10.</citation>
    <PMID>16686940</PMID>
  </reference>
  <reference>
    <citation>Hare KM, Morris P, Smith-Vaughan H, Leach AJ. Random colony selection versus colony morphology for detection of multiple pneumococcal serotypes in nasopharyngeal swabs. Pediatr Infect Dis J. 2008 Feb;27(2):178-80. doi: 10.1097/INF.0b013e31815bb6c5.</citation>
    <PMID>18174871</PMID>
  </reference>
  <reference>
    <citation>Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006 Mar 4;367(9512):740-8.</citation>
    <PMID>16517274</PMID>
  </reference>
  <reference>
    <citation>Roche PW, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, Fielding J, Giele C, Gilmour R, Holland R, Kampen R; Enhanced Invasive Pneumococcal Disease Surveillance Working Group, Brown M, Gilbert L, Hogg G, Murphy D; Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell Q Rep. 2008 Mar;32(1):18-30.</citation>
    <PMID>18522302</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>otitis media</keyword>
  <keyword>pneumococcal vaccines</keyword>
  <keyword>randomised controlled trial</keyword>
  <keyword>high-risk children</keyword>
  <keyword>indigenous</keyword>
  <keyword>Australia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

